ZSP1273

Phase 3Small molecule

GGuangdong Raynovent Biotech Co., Ltd

ZSP1273 is one of 59 small molecule programs targeting Kidney Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney DiseaseActive, not recruiting

InfluenzaActive, not recruiting

Kidney DiseasePhase 1

Active, not recruiting

InfluenzaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

ZSP1273

GGuangdong Raynovent Biotech Co., Ltd

Phase 3

5 2

Fluzone

Sanofi

Preclinical

16 3

Fluzone

GSK

Preclinical

37 4

Crestor

AstraZeneca

Preclinical

1 5

Trexall

Alnylam Pharmaceuticals

Preclinical

1 6

Avigan

AAppili Therapeutics Inc.

Preclinical

6 7

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 8

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 9

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1 10

Fluvirin

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Influenza5 trials

Pharmacokinetics，Safety and Efficacy of ZSP1273 in Children 2-17 Years Old With Influenza A

Completed·GGuangdong Raynovent Biotech Co., Ltd·Phase 2·NCT06656026·72 enrolled

Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A

Active, not recruiting·GGuangdong Raynovent Biotech Co., Ltd·Phase 3·NCT07229807·119 enrolled

Efficacy and Safety of ZSP1273 in Children 12-17 Years Old With Influenza A

Active, not recruiting·GGuangdong Raynovent Biotech Co., Ltd·Phase 3·NCT07229820·157 enrolled

Show 2 more trials

Study of ZSP1273 in Patients With Acute Uncomplicated Influenza A

Completed·GGuangdong Raynovent Biotech Co., Ltd·Phase 2·NCT04024137·172 enrolled

A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A

Completed·GGuangdong Raynovent Biotech Co., Ltd·Phase 3·NCT04683406·750 enrolled

Interaction3 trials

A Drug Interaction Study Assess the Effects of ZSP1273 Tablets on the Pharmacokinetics of Warfarin and Midazolam

Completed·GGuangdong Raynovent Biotech Co., Ltd·Phase 1·NCT05942365·28 enrolled

Drug-durg Interaction of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and Probenecid

Completed·GGuangdong Raynovent Biotech Co., Ltd·Phase 1·NCT05954624·49 enrolled

Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir

Completed·GGuangdong Raynovent Biotech Co., Ltd·Phase 1·NCT05108051·36 enrolled

Tics1 trial

Pharmacokinetics of ZSP1273 in Elder Participants

Completed·GGuangdong Raynovent Biotech Co., Ltd·Phase 1·NCT06157450·32 enrolled

Kidney Disease1 trial

Pharmacokinetics of ZSP1273 in Participants With Severe Kidney Disease

Completed·GGuangdong Raynovent Biotech Co., Ltd·Phase 1·NCT06248567·16 enrolled

Hepatic Impairment1 trial

Pharmacokinetics of ZSP1273 in Participants With Hepatic Impairment

Completed·GGuangdong Raynovent Biotech Co., Ltd·Phase 1·NCT05856513·24 enrolled

3 more indications

ART1 trial

Bioavailability Study in Healthy Participants, 200mg Tablets ZSP1273 Versus 200mg Granules ZSP1273

Completed·GGuangdong Raynovent Biotech Co., Ltd·Phase 1·NCT06164431·32 enrolled

Adult1 trial

Mass Balance Study of [14C]ZSP1273 in Healthy Adult Male Subjects in China

Completed·GGuangdong Raynovent Biotech Co., Ltd·Phase 1·NCT05873426·6 enrolled

Unspecified1 trial

The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers.

Completed·GGuangdong Zhongsheng Pharmaceutical Co., Ltd.·Phase 1·NCT03679143·103 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for ZSP1273. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ZSP1273 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ZSP1273. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangdong Raynovent Biotech Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGuangdong Raynovent Biotech Co., Ltd

ZSP1273

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Influenza5 trials

Interaction3 trials

Tics1 trial

Kidney Disease1 trial

Hepatic Impairment1 trial

ART1 trial

Adult1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News